NCT05528367

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma：A Single Arm Phase II Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.

Conditions

• Locally Advanced Gastric Cancer

Interventions

Type	Name	Description
DRUG	Nab-PTX,S-1,Tirelizumab	S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily. Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w.
RADIATION	Chemoradiation	45-50Gy/25F

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-06-30
• Completion: 2024-12-31
• First posted: 2022-09-06
• Last updated: 2022-09-06

Locations

1 site across 1 country: China